SIRT1 was identified as a direct target for miR-22, and miR-22 might act as a tumor suppressor in RCC and blocks RCC growth and metastasis by direct targeting of SIRT1, indicating a potential new therapeutic effect in RCC therapy45. The gene discussed is SIRT1; the disease is renal cell carcinoma.